

Shionogi Announces the Conducting of International Industry-Academic Collaboration, SHIONOGI Science Program, and Drug Discovery Competition, FINDS2011

Osaka, October 3, 2011 – Shionogi & Co., Ltd. (Head Office: Osaka; President & CEO: Isao Teshirogi, Ph.D.; hereafter “Shionogi”) implements international industry-academic collaboration, SHIONOGI Science Program (SSP) in the United Kingdom (UK). Moreover, Shionogi publicly invites researchers in Japan to enter their innovative ideas in its drug discovery competition, FINDS (PHarma-INnovation Discovery competition Shionogi).

The SSP is a collaborative industry-academia initiative in which researchers with innovative drug seeds can submit ideas that meet Shionogi’s specified needs and work with the company to develop them into commercially viable drugs. This is the first time that Shionogi has focused on overseas researchers.

In Japan, Shionogi has implemented the same program, FINDS since 2007.

The aims of SSP, similar to FINDS focused on Japan, are to discover and develop innovative ideas to promote the research in Shionogi with worldwide views by a global perspective of industry-academia collaboration, and to foster open innovation amongst young researchers.

This competition round is also open to UK and Japanese researchers who wish to collaborate with UK researchers.

This program is one of concrete approaches based on the international university- industry cooperation network of the research and development that concluded UK with the agreement in October, 2009. Shionogi works in close cooperation with 14 universities in UK which have signed Memorandum of Understanding.

Through these initiatives including SSP and FINDS, Shionogi will establish the presence as an international company and continue to develop new drugs for patients who suffer from diseases around the world.

Competition Overview 【SSP】

1.Application period: 3.00pm 2nd October 2011 - 10:00pm 30th October 2011 (UK time)

2.Application areas:

- Drug discovery in specified disease areas
- Ideas for novel next generation biologics
- Ideas for novel technology of drug formulation

3.Applicants: For UK: Researchers must carry out their research in UK.

For Japan: Researchers of universities can apply in cases of joint research with UK universities (Researchers of Japanese universities are asked to apply under the FINDS program in cases of standalone research.)

4.Selection method: Two-stage process

5.Selection criteria: Submissions will be assessed and selected on the basis of factors including degree of correspondence with Shionogi's needs, originality, practicality, possibility, potential for industrialization and conflict with existing company projects.

6.Research budget: 5 million to 15 million yen per project

It covers the staff costs of staff on exclusive contracts. It cannot be used to fund students or scholarships.

Please refer to web site here for details. <http://www.shionogi.co.jp/ssp/index.html>

14 universities of UK

Cardiff University, Imperial College London, King's College London, University of Aberdeen, University of Bath, University of Bristol, University of Dundee, University of Edinburgh, University of Glasgow, University of Leeds, University of Liverpool, University of Manchester, University of Oxford, University of Strathclyde

Competition Overview 【FINDS】

1.Application period: 10:00am 3rd October 2011 - 5.00pm 31st October 2011

2.Application areas: Drug seeds for diabetes, obesity, dyslipidemia, arteriosclerosis and chronic kidney diseases. Drug seeds for HIV and "emerging and reemerging infectious diseases", etc.

3.Selection method: Two-stage process

4.Selection criteria: Submissions will be assessed and selected on the basis of factors including degree of correspondence with Shionogi's needs, originality, practicality, possibility, potential for industrialization and conflict with existing company projects.

5.Research budget: 5 million to 10 million yen per project

- It contains the employment expense who is engaged in under exclusive contract.
- It is not for scholarship.

Please refer to web site here for details. <http://www.shionogi.co.jp/finds/index.html>

Forward-Looking Statements

This announcement contains forward-looking statements. These statements are based on expectations in light of the information currently available, assumptions that are subject to risks and uncertainties which could cause actual results to differ materially from these statements. Risks and uncertainties include general domestic and international economic conditions such as general industry and market conditions, and changes of interest rate and currency exchange rate. These risks and uncertainties particularly apply with respect to product-related forward-looking statements. Product risks and uncertainties include, but are not limited to, completion and discontinuation of clinical trials; obtaining regulatory approvals; claims and concerns about product safety and efficacy; technological advances; adverse outcome of important litigation; domestic and foreign healthcare reforms and changes of laws and regulations. Also for existing products, there are manufacturing and marketing risks, which include, but are not limited to, inability to build production capacity to meet demand, unavailability of raw materials and entry of competitive products. The company disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information, future events or otherwise.

Inquiries : Make inquiries via the "Inquiries Form" on the website.